Fenwick & West LLP represented Vancouver, British Columbia's Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) in the licensing agreement that provides HTG Molecular Diagnostics exclusive rights to commercialize gene expression tests for prognosis of PROOF Centre patients who will experience frequent lung attacks. HTG said it plans to use PROOF Centre's testing technology to develop an assay on its qNPA platform. PROOF Centre will be involved in the clinical validation in Canada and provide key opinion leader support for regulatory approval in North America.
The license agreement will help bring these prognostic tests to market faster and will improve patient care and alleviate the suffering of PROOF Centre patients by enabling doctors to tailor their treatments to match the patients' needs sooner.
The Fenwick transaction team included technology transaction partner E.A. Lisa Kenkel and patent partner Andrew T. Serafini, Ph.D.